A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Exclusion criteria

• ✕. Posterior nostril polyps;
• ✕. Imaging suspected or confirmed fungal sinusitis;
• ✕. Nasal polyp score(NPS) cannot be evaluated due to nasal surgery to alter the structure of the lateral nasal wall;
• ✕. Subjects with nasal malignancies and benign tumors (papilloma, blood furuncle, etc.).
• ✕. Immunosuppressive therapy had been administered within the previous 8 weeks or five half-lives (whichever was longer), (including but not limited to cyclophosphamide, cyclosporine, interferon-γ, azathioprine, methotrexate, mycophenolate mofetil and tacrolimus, etc.);
• ✕. Monoclonal antibody therapy had been administered within the previous 8 weeks or five half-lives (whichever was longer), (Including but not limited to: benralizumab, mepolizumab, omalizumab, resveratrol, dupilumab, etc.);
• ✕. Systemic glucocorticoids were used during the first 28 days;
• ✕. Glucocorticoid-eluting nasal stents were used during the first 6 mouths;